ZA200201619B - Use of amino acids for making medicines for treating to insulin-resistance. - Google Patents

Use of amino acids for making medicines for treating to insulin-resistance. Download PDF

Info

Publication number: ZA200201619B
Authority: ZA; South Africa
Prior art keywords: insulin; composition; substance; manufacture; treatment
Prior art date: 1999-08-27

Application number

ZA200201619A

Other languages

English (en)

Inventor

Gerard Ribes

Pierre Roger Petit

Yves Sauvaire

Mohammed Taouis

Christophe Broca

Bernard Pau

Original Assignee

Innodia

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-27

Filing date

2002-02-26

Publication date

2003-07-30

2002-02-26 Application filed by Innodia filed Critical Innodia

2003-07-30 Publication of ZA200201619B publication Critical patent/ZA200201619B/en

Links

239000003814 drug Substances 0.000 title claims abstract description 31
150000001413 amino acids Chemical class 0.000 title claims abstract description 27
208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 27
206010022489 Insulin Resistance Diseases 0.000 title claims abstract description 25
229940079593 drug Drugs 0.000 title abstract description 3
238000011282 treatment Methods 0.000 claims abstract description 28
150000002596 lactones Chemical class 0.000 claims abstract description 5
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 144
230000000694 effects Effects 0.000 claims description 76
102000004877 Insulin Human genes 0.000 claims description 72
108090001061 Insulin Proteins 0.000 claims description 72
229940125396 insulin Drugs 0.000 claims description 72
239000000203 mixture Substances 0.000 claims description 22
102000003746 Insulin Receptor Human genes 0.000 claims description 20
108010001127 Insulin Receptor Proteins 0.000 claims description 20
238000000034 method Methods 0.000 claims description 20
239000000126 substance Substances 0.000 claims description 20
238000004519 manufacturing process Methods 0.000 claims description 18
150000001875 compounds Chemical class 0.000 claims description 17
OSCCDBFHNMXNME-UHFFFAOYSA-N gamma-hydroxyisoleucine Natural products CC(O)C(C)C(N)C(O)=O OSCCDBFHNMXNME-UHFFFAOYSA-N 0.000 claims description 16
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims description 12
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 12
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 12
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 12
201000008980 hyperinsulinism Diseases 0.000 claims description 9
230000011664 signaling Effects 0.000 claims description 8
206010060378 Hyperinsulinaemia Diseases 0.000 claims description 7
230000003451 hyperinsulinaemic effect Effects 0.000 claims description 7
230000002093 peripheral effect Effects 0.000 claims description 7
206010028980 Neoplasm Diseases 0.000 claims description 6
208000008589 Obesity Diseases 0.000 claims description 6
201000011510 cancer Diseases 0.000 claims description 6
235000020824 obesity Nutrition 0.000 claims description 6
102100025092 Insulin receptor substrate 2 Human genes 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
230000035755 proliferation Effects 0.000 claims description 4
208000011580 syndromic disease Diseases 0.000 claims description 4
102100025087 Insulin receptor substrate 1 Human genes 0.000 claims description 3
101710201820 Insulin receptor substrate 2 Proteins 0.000 claims description 3
230000032683 aging Effects 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
OSCCDBFHNMXNME-WDCZJNDASA-N (2s,3s,4r)-2-amino-4-hydroxy-3-methylpentanoic acid Chemical compound C[C@@H](O)[C@@H](C)[C@H](N)C(O)=O OSCCDBFHNMXNME-WDCZJNDASA-N 0.000 claims 4
239000002253 acid Substances 0.000 claims 3
150000007513 acids Chemical class 0.000 claims 3
101710201824 Insulin receptor substrate 1 Proteins 0.000 claims 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
230000002401 inhibitory effect Effects 0.000 claims 2
230000001668 ameliorated effect Effects 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
235000001014 amino acid Nutrition 0.000 description 18
229940024606 amino acid Drugs 0.000 description 18
210000004185 liver Anatomy 0.000 description 16
OSCCDBFHNMXNME-YUPRTTJUSA-N (4S)-4-hydroxy-L-isoleucine zwitterion Chemical compound C[C@H](O)[C@H](C)[C@H](N)C(O)=O OSCCDBFHNMXNME-YUPRTTJUSA-N 0.000 description 13
241000700159 Rattus Species 0.000 description 13
102000005962 receptors Human genes 0.000 description 10
108020003175 receptors Proteins 0.000 description 10
230000026731 phosphorylation Effects 0.000 description 9
238000006366 phosphorylation reaction Methods 0.000 description 9
210000003205 muscle Anatomy 0.000 description 8
230000004913 activation Effects 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
210000001519 tissue Anatomy 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 5
206010012601 diabetes mellitus Diseases 0.000 description 5
238000010586 diagram Methods 0.000 description 5
108020000494 protein-tyrosine phosphatase Proteins 0.000 description 5
230000009467 reduction Effects 0.000 description 5
230000009471 action Effects 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
230000002440 hepatic effect Effects 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000000758 substrate Substances 0.000 description 4
108091008606 PDGF receptors Proteins 0.000 description 3
108091000080 Phosphotransferase Proteins 0.000 description 3
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 3
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
230000008901 benefit Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
239000012133 immunoprecipitate Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
102000020233 phosphotransferase Human genes 0.000 description 3
239000000047 product Substances 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 2
102000043136 MAP kinase family Human genes 0.000 description 2
108091054455 MAP kinase family Proteins 0.000 description 2
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
108091007960 PI3Ks Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
244000250129 Trigonella foenum graecum Species 0.000 description 2
235000001484 Trigonella foenum graecum Nutrition 0.000 description 2
229940093740 amino acid and derivative Drugs 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
230000001904 diabetogenic effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000003387 muscular Effects 0.000 description 2
230000007170 pathology Effects 0.000 description 2
150000003905 phosphatidylinositols Chemical class 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
-1 type 1 diabetes Chemical compound 0.000 description 2
238000011684 zucker rat (obese) Methods 0.000 description 2
101100205088 Caenorhabditis elegans iars-1 gene Proteins 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108700038106 Glucose transporter GLUT Proteins 0.000 description 1
102000052484 Glucose transporter GLUT Human genes 0.000 description 1
101150030450 IRS1 gene Proteins 0.000 description 1
208000031773 Insulin resistance syndrome Diseases 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
208000037849 arterial hypertension Diseases 0.000 description 1
230000035578 autophosphorylation Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000001609 comparable effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
238000000329 molecular dynamics simulation Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
230000002969 morbid Effects 0.000 description 1
229960003966 nicotinamide Drugs 0.000 description 1
235000005152 nicotinamide Nutrition 0.000 description 1
239000011570 nicotinamide Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
235000017924 poor diet Nutrition 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000005180 public health Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000001235 sensitizing effect Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
102000027257 transmembrane receptors Human genes 0.000 description 1
108091008578 transmembrane receptors Proteins 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
239000001917 trigonella foenum graecum l. absolute Substances 0.000 description 1
235000001019 trigonella foenum-graecum Nutrition 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
235000002374 tyrosine Nutrition 0.000 description 1
150000003668 tyrosines Chemical class 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA200201619A 1999-08-27 2002-02-26 Use of amino acids for making medicines for treating to insulin-resistance. ZA200201619B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9910874A FR2797767B1 (fr)	1999-08-27	1999-08-27	Utilisation d'acides amines pour la fabrication de medicaments destines au traitement des insulino-resistances

Publications (1)

Publication Number	Publication Date
ZA200201619B true ZA200201619B (en)	2003-07-30

Family

ID=9549397

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200201619A ZA200201619B (en)	1999-08-27	2002-02-26	Use of amino acids for making medicines for treating to insulin-resistance.

Country Status (14)

Country	Link
US (2)	US7402611B1 (da)
EP (2)	EP1206257B1 (da)
JP (1)	JP2003508435A (da)
CN (1)	CN1208055C (da)
AT (1)	ATE281159T1 (da)
AU (1)	AU7015700A (da)
CA (1)	CA2382835A1 (da)
DE (1)	DE60015560T2 (da)
DK (1)	DK1206257T3 (da)
ES (1)	ES2231247T3 (da)
FR (1)	FR2797767B1 (da)
PT (1)	PT1206257E (da)
WO (1)	WO2001015689A1 (da)
ZA (1)	ZA200201619B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7338675B2 (en) *	2002-05-10	2008-03-04	Tsi Health Sciences, Inc.	Fenugreek seed bio-active compositions and methods for extracting same
FR2847897B1 (fr) *	2002-12-02	2006-02-24	Centre Nat Rech Scient	Procede de preparation de diasteroisomeres et d'enantiomeres de la 4-hydroxyisoleucine et de ses derives
EP1609780A4 (en)	2003-03-19	2007-09-05	Kyowa Hakko Kogyo Kk	MEANS FOR THE TREATMENT OF DIABETES
FR2856297B1 (fr) *	2003-06-18	2005-08-05	Caster	Utilisation de (2s,3r,4s)-4-hydroxyisoleucine dans des compositions cosmetiques pour application topique
BRPI0415781A (pt) *	2003-10-27	2006-12-26	Innodia Inc	método para o tratamento de diabetes em um paciente e kit farmacêutico
US7645466B2 (en)	2004-03-02	2010-01-12	Tsi Group Limited	Methods for deriving, isolating, and/or extracting amino acid compositions from Fenugreek seed
WO2006017157A1 (en) *	2004-07-09	2006-02-16	Pure World Botanicals, Inc.	Weight loss composition
BRPI0607140A2 (pt) *	2005-02-18	2009-08-11	Innodia Inc	composto, uso do composto e/ou uso de um sal, lactona ou pró-medicamento farmaceuticamente aceitável do dito composto, composição farmacêutica, kit farmacêutico, método para estimular a captação de glicose pelas células musculares e/ou células de adipócito, método para estimular a secreção de insulina pelas células pancreáticas células-(beta) e método para o tratamento de um mamìfero que tem um distúrbio do metabolismo de carboidratos ou de lipìdios
EP1874287A2 (en) *	2005-03-22	2008-01-09	Innodia Inc.	Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
WO2007107008A1 (en) *	2006-03-22	2007-09-27	Innodia Inc.	Compounds and compositions for use in the prevention and treatment of disorders of fat metabolism and obesity
US20100124583A1 (en) *	2008-04-30	2010-05-20	Xyleco, Inc.	Processing biomass
WO2008102671A1 (ja)	2007-02-22	2008-08-28	Ajinomoto Co., Inc.	４－ヒドロキシイソロイシンの精製方法
NZ606047A (en)	2008-04-30	2015-03-27	Xyleco Inc	Processing biomass
CN108078973A (zh) *	2017-12-25	2018-05-29	郑州大学	4-羟基异亮氨酸的新用途
CN112089710B (zh) *	2020-08-07	2022-04-01	郑州大学	4-羟基异亮氨酸在制备抗肿瘤药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU1011126A1 (ru) *	1981-07-14	1983-04-15	Всесоюзный научно-исследовательский и испытательный институт медицинской техники	Средство дл лечени сахарного диабета
US5178867A (en) *	1991-08-19	1993-01-12	Alza Corporation	Dosage form for delivering drug in short-time period
US5591709A (en) *	1991-08-30	1997-01-07	Life Medical Sciences, Inc.	Compositions and methods for treating wounds
FR2695317B1 (fr) *	1992-09-07	1995-03-10	Monal Lab	Composition apte à stimuler la sécrétion d'insuline destinée au traitement du diabète non insulino-dépendant.
IL108583A (en)	1994-02-07	1997-06-10	Yissum Res Dev Co	Galactomannan emulsions and comestible products containing the same
GB9517443D0 (en) *	1994-12-17	1995-10-25	Univ Nottingham	Increasing creatine and glycogen concentration in muscle
FR2745718B1 (fr) *	1996-03-08	1998-05-07	Gestion Jouvenet Soc Civ De	Composition antidiabetique a base de 4-hydroxyisoleucine
AU7181198A (en) *	1996-11-13	1998-06-03	Receptron Corporation	Assays for non-insulin dependent diabetes
JP2002512685A (ja) *	1997-01-15	2002-04-23	テリック・インコーポレイテッド	インスリン受容体活性のモジュレーター
CA2206157C (en)	1997-05-26	2000-06-13	Cheng, Peter	Method of extraction of commercially valuable fractions of fenugreek

1999
- 1999-08-27 FR FR9910874A patent/FR2797767B1/fr not_active Expired - Fee Related
2000
- 2000-08-23 US US10/069,574 patent/US7402611B1/en not_active Expired - Fee Related
- 2000-08-23 JP JP2001519903A patent/JP2003508435A/ja active Pending
- 2000-08-23 EP EP00958726A patent/EP1206257B1/fr not_active Expired - Lifetime
- 2000-08-23 CA CA002382835A patent/CA2382835A1/fr not_active Abandoned
- 2000-08-23 AU AU70157/00A patent/AU7015700A/en not_active Abandoned
- 2000-08-23 ES ES00958726T patent/ES2231247T3/es not_active Expired - Lifetime
- 2000-08-23 AT AT00958726T patent/ATE281159T1/de not_active IP Right Cessation
- 2000-08-23 DK DK00958726T patent/DK1206257T3/da active
- 2000-08-23 EP EP03291523A patent/EP1421937A1/fr not_active Withdrawn
- 2000-08-23 WO PCT/FR2000/002361 patent/WO2001015689A1/fr not_active Ceased
- 2000-08-23 DE DE60015560T patent/DE60015560T2/de not_active Expired - Fee Related
- 2000-08-23 PT PT00958726T patent/PT1206257E/pt unknown
- 2000-08-23 CN CNB008133166A patent/CN1208055C/zh not_active Expired - Fee Related
2002
- 2002-02-26 ZA ZA200201619A patent/ZA200201619B/en unknown
2008
- 2008-07-21 US US12/176,827 patent/US20080287344A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1206257B1 (fr)	2004-11-03
ATE281159T1 (de)	2004-11-15
PT1206257E (pt)	2005-03-31
US7402611B1 (en)	2008-07-22
EP1206257A1 (fr)	2002-05-22
WO2001015689A1 (fr)	2001-03-08
EP1421937A1 (fr)	2004-05-26
CN1208055C (zh)	2005-06-29
DK1206257T3 (da)	2005-03-14
HK1052456A1 (en)	2003-09-19
CA2382835A1 (fr)	2001-03-08
DE60015560D1 (de)	2004-12-09
AU7015700A (en)	2001-03-26
ES2231247T3 (es)	2005-05-16
FR2797767B1 (fr)	2002-06-14
CN1376062A (zh)	2002-10-23
DE60015560T2 (de)	2005-12-15
FR2797767A1 (fr)	2001-03-02
US20080287344A1 (en)	2008-11-20
JP2003508435A (ja)	2003-03-04

Publication	Publication Date	Title
US20080287344A1 (en)	2008-11-20	Use of Amino Acids for Making Medicines for Treating Insulin Resistance
ES2311117T3 (es)	2009-02-01	Combinacion de un inhibidor de dpp-iv y un compuesto ppar-alfa.
ES2402522T3 (es)	2013-05-06	Composiciones y procedimientos para aumentar la sensibilidad a la insulina
JP6250588B2 (ja)	2017-12-20	Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
RU2199316C2 (ru)	2003-02-27	Вещества, подавляющие рефлюкс
Nyström	2008	The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance
US7081473B2 (en)	2006-07-25	Agent for preventing/ameliorating obesity comprising methylidene hydrizide compound as active ingredient
Movahednasab et al.	2025	GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation
JPH08503451A (ja)	1996-04-16	癌治療のモダリティーとしての３‐ヒドロキシ‐３‐メチルグルタリルＣｏＡレダクターゼ阻害剤の使用
EP1997485A1 (en)	2008-12-03	Pharmaceutical composition comprising meglitinide for prevention of hepatic fibrosis
IL117518A (en)	2001-05-20	The use of the product of aminotterlin to prepare a drug for the treatment of cardiovascular disease
JP6978126B2 (ja)	2021-12-08	肥満関連代謝疾患の改善剤
TW202404616A (zh)	2024-02-01	鼠李糖在製備用於治療或預防神經退行性疾病的藥物中的用途、藥物組合物及其應用
JP2022544718A (ja)	2022-10-21	敗血症性心筋症を治療するための組成物および方法
AU766230B2 (en)	2003-10-09	Aminotetralin derivative for the therapy of cardiovascular diseases
EA018442B1 (ru)	2013-08-30	Применение l-карнитина для лечения гипертензии, для снижения систолического или пульсового давления крови у субъектов с предиабетом
HK1052456B (en)	2005-10-28	Use of amino acids for making medicines for treating insulin-resistance
HK1068537A (en)	2005-04-29	Use of amino acids for making medicines for treating insulin-resistance
US20120065267A1 (en)	2012-03-15	Compositions including 3,5-l-t2 and methods of use thereof
US20230190682A1 (en)	2023-06-22	Pharmaceutical composition for preventing or treating metabolic diseases
JP5217436B2 (ja)	2013-06-19	Ａｋｔ活性化抑制剤
KR20070015114A (ko)	2007-02-01	3,3,14,14 테트라메틸 헥사데칸 1,16 이산의 투여 방법
WO2017202297A1 (zh)	2017-11-30	三乙酰基-3-羟基苯基腺苷在治疗血管炎症或改善血管内皮功能中的应用
KR20210089176A (ko)	2021-07-15	통풍 또는 고요산혈증의 치료를 위한 의약품의 제조에서의 화합물 a 및 화합물 b의 공동 용도
WO2010098475A1 (ja)	2010-09-02	摂食障害予防及び治療剤